KCT0003294招募中未知
The I-phase clinical trial of high-capacity Simvastatin in patients with gastrointestinal cancer that failed standard chemotherapy
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Test subjects with the intent and ability to provide written consent/approval for this clinical trial.
- •2. Test subjects with an age of 20 or older at the time of signing the consent of the test subjects (or the higher of acceptable age according to local regulations).
- •3. Organically or cytologically tested for colorectal or gastric cancer
- •4. In case of colon cancer, treatment (cetRuxMab) was performed only after 5FU or capecetamine, irinotcan, octifatin, bvacizumab and cetuximab
- •5. In case of stomach cancer, subjects tested after secondary chemotherapy.
- •6.Test subjects with a status of 0 or 1 on the ECOG performance scale.
- •7. Test subjects who determined that there was a disease that could be assessed based on RECIST v1.1
- •8.PK test subjects willing to provide blood samples for analysis.
- •9. Test subjects to swallow and maintain oral medication.
- •10. Test subjects tested for proper long-term capability. All screening clinical laboratory examinations are conducted within 14 days prior to commencement of treatment.
- •Table 1 Clinical laboratory values for appropriate long-term functions
- •Clinical laboratory figures
- •(hematology)
- •Absolute neutrophil count =1,500 /mCL
- •Platelets =100,000 / mCL
- •Hemoglobin =9 g/dL
- •serum creatine or
- •Measured or calculateda creatine cleaning rate
- •(GFR (Glomerular Filtering Rate) =1.5 X Normal (ULN:upper limits)
- •instead of creatine or CrCl
- •60mL/min for test subjects with creatine level > 1.5X testing agency ULN
- •Total serum bilirubin = 1.5 ULN
- •AST (SGOT) and ALT (SGPT) = 3 X ULN
- •(blood clotting)
- •International Normalization Ratio (INR) or Protrombin Time (PT)
- •Enabled Partial Tromboplastin Time (aPTT) If the test subjects are not receiving anticoagulance therapy and the PT or PTT is within the therapeutic range of the intended anticoagulant use =
- •= ULN if the test subjects are not receiving anticoagulance therapy and PTT or PTT is within the therapeutic range of the intended anticoagulant use.
- •aCretin cleaning rate shall be calculated in accordance with the testing agency standard.
- •11. Female test subjects should have a urine or serum pregnancy test voice within 72 hours prior to administration of the initial dose of the test drug. If the urine test is positive or negative, a serum pregnancy test is required.
- •12. Female test subjects are willing to use two methods of contraception, surgical infertility, or heterosexual sex during the clinical trial until 120 days after the final dose of the drug. The test subjects are women who are not clinically infertile or have no menstrual periods for one year.
- •13. Male test subjects should agree to use appropriate contraception starting with the initial administration of clinical trial treatments until 120 days after final administration of clinical trial treatments.
排除标准
- •1. Past history of use of statins within 12 months of clinical trial participation
- •2. Test subjects with severe revenge or metastatic fracture
- •3.Active central nervous system (CNS) transfer and/or cancer meningitis are known to be tested. Test subjects with previously treated brain transitions are stable (if they are not used for at least four weeks prior to the initial administration of clinical trial treatments, there is no evidence of at least seven weeks of progress by video, and no evidence of new or extended brain transfer). This exception does not include cancerous meningitis, which excludes clinical stability.
- •4. Additional malignant tumors that are currently in progress or require active treatment are tested. Exceptions include skin basal cell carcinoma or skin flat cell cancer or cervical cervical cervical endodermal cancer, which has been treated with potential full-treatment.
- •5. Test subjects with active infection requiring telemedicine.
- •6. Disrupting or participating in clinical trial results as determined by the treatment tester or disrupting participation of test subjects during the entire clinical trial period has a history or current evidence of any condition, therapy or clinical laboratory abnormalities for the test subjects.
- •7. Persons who are tested for mental or substance abuse that may interfere with cooperation in clinical testing requirements.
- •8. A person who is pregnant or breastfeeding, or who plans to become pregnant or father of a child within the expected clinical trial period of 120 days after the final dose of a clinical trial treatment, starting with a pre-scanning or screening visit.
- •9. Test subjects whose past history of the human immunodeficiency virus (HIV) (HIV 1/2 antibody) is known.
- •10. Test target with CPK > ULN in the baseline.
- •11. Powerful CYP3A4 inhibitors, such as Clarithromycin, erythromzzanine, itraconazole, nefazone, etc.
- •12. A person with a history of muscular dystrophy/translipidosis (including patients with rhabdomyolysis or muscular dystrophy with statin or fibrate medication)
- •13. Patients whose CK level has increased more than five times their normal limit during previous treatment of statins
- •14. Unregulated hypothyroidism
- •15.Galactose intolerance, lapp lactase deficiency, or glucose-alactose absorption
研究者
相似试验
已完成
1 期
A phase 1 clinical pharmacological study with a single oral dose of KAG-308JPRN-UMIN000011878Kaken Pharmaceutical Co., LTD60
进行中（未招募）
1 期
Pilot study of SIR-Spheres plus systemic chemotherapy with irinotecan alone in patients with non-resectable liver metastases from primary adenocarcinoma of the large bowelMetastatic colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12606000009516Sirtex Medical Limited37
进行中（未招募）
1 期
Trial on safety and activity of intensive short-term chemoimmunotherapy in patients with AIDS affected by Burkitt's lymphoma.Burkitt's lymphoma in HIV-positive patients.MedDRA version: 14.1Level: PTClassification code 10006595Term: Burkitt's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003487-75-ITFONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR19
已完成
1 期
A clinical trial of SIIL's H1N1 vaccine (Inactivated) in Adults.CTRI/2010/091/000082Serum Institute of India Limited SII50
招募中
Unknown
Investigation of clinical availability of new simple tracheal intubation method using brochofibersopeJPRN-UMIN000053976Kishiwada Tokushukai Hospital50